All News
Best of 2023: Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read Article
ICYMI: Effective Treatments for Rheumatoid Arthritis ILD
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Read Article
RheumNow Podcast – Bill of Rights (12.15.2023)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery.
Read Article
Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA
d
MedPage Today
Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.
Read Article
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/NL8yJ9CdvQ https://t.co/dUUXyWYbsT
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA
High Eosinophil counts in Stable RA - what's the differential Dx?.
https://t.co/r7DHil4u9B https://t.co/rTAGUcgd1C
Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/xOYfEs16ou https://t.co/MzEPpUc7Eb
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Recommendations on Fatigue
Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life.
https://t.co/ETYyCnykj7 https://t.co/c2DEWrvqZb
Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/iBIreoNrXx https://t.co/xh4rWdKbGT
Dr. John Cush RheumNow ( View Tweet)
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/rJSqLwQW1S https://t.co/w3ZpdVQYNL
Dr. John Cush RheumNow ( View Tweet)
Hemophagocytic Lymphohistiocytosis in Still's disease
Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77
Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy
The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy
Dr. John Cush RheumNow ( View Tweet)
Korean ULTRA registry studied 117 Gout pts starting ULT; compared T2T achievers (SUA< 6) vs non-achievers. @6 mos, 71% reached target SUA (w/ better adherence (98% vs. 76%) than non-achievers. T2T achievers assoc w/ good adherence, +FamHx, & HTN meds https://t.co/wTuvPqcan5 https://t.co/QD9j923sSa
Dr. John Cush RheumNow ( View Tweet)
Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6
Dr. John Cush RheumNow ( View Tweet)
FINAL DAY for early bird pricing for RheumNow Live.
Take advantage of this discounted price TODAY!
https://t.co/UW9SMjEBYB https://t.co/DX2SJZYkUW
Links:
Dr. John Cush RheumNow ( View Tweet)
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/Hhxr7hscaL https://t.co/J46JvHwRmc
Dr. John Cush RheumNow ( View Tweet)
Clinical Practice Res Database studied 51K gout pts before ULT therapy, 36% had ≥ 1 recurrent flares, 17% flared w/in 12 mos of Dx. Flares risk: Male, blacks, obese, CHF, CKD, CVD, diuretics, Hi SUA (HR 4.6). Only 28% Given ULT w/in 12 mos of Dx https://t.co/TAHBDxA6Th https://t.co/rwztpe7y2r
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA
High Eosinophil counts in Stable RA - what's the differential Dx?.
https://t.co/au606vNQob https://t.co/VJneBfGr4P
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to #ACR23 there has been relatively little to say about how to treat it.
https://t.co/FnygxtDwx8 https://t.co/2j1nbsAAp0
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab
Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups.
https://t.co/wn5iDXibzi https://t.co/IVtKwdYDwN
Dr. John Cush RheumNow ( View Tweet)